首页> 外文OA文献 >Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.

【2h】

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.

机译：对照分析和预测疗效的可能性，用于IL-13生物制药治疗支气管哮喘的川曲单抗和lebrikizumab。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Yutaka Nakamura; Aki Sugano; Mika Ohta; Yutaka Takaoka;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Anti-IL-13 mAb(anrukinzumab，lebrikizumab, tralokinumab)の現状と今後の展開 [J] . 洲崎勲夫臨床免疫·アレルギー科 . 2017,第2期

机译：抗IL-13 mAb的现状和未来发展（anrukinzumab，lebrikizumab，tralokinumab）
2. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) [J] . Simpson Eric L., Flohr Carsten, Eichenfield Lawrence F., Journal of the American Academy of Dermatology . 2018,第5期

机译：lebrikizumab（抗IL-13单克隆抗体）在成人中具有中度至严重的特征性皮炎的疗效和安全性因局部皮质类固醇不足：随机，安慰剂控制的第二阶段试验（高音）
3. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb [J] . Wollenberg Andreas, Howell Michael D., Guttman-Yassky Emma, The Journal of Allergy and Clinical Immunology . 2019,第1期

机译：用抗IL-13 mAb治疗特特酸的特应性皮炎
4. Molecular Docking Analysis of Leucaena leucocephala and Trigonella foenum-graecum Chemical Constituents on Antidiabetic Macromolecular Targets and Prediction of the Pharmacokinetic Profiles [C] . V. Nurmaylindha, G. P. Widodo, R. Herowati International Conference of the Indonesian Chemical Society . 2020

机译：Leucaena Leucocephala和Trigonella foenum-Graecum Computics的分子对接分析对抗糖尿病大分子靶标的预测和预测药代动力学谱
5. Acute renal failure: Cost -effectiveness analysis and expert probability predictions of prevention and treatment strategies. [D] . Durtschi, Amy Jean. 2003

机译：急性肾衰竭：成本效益分析和专家对预防和治疗策略的概率预测。
6. Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma [O] . Yutaka Nakamura, Aki Sugano, Mika Ohta, 2011

机译：曲妥珠单抗和来昔单抗抗IL-13生物药物治疗支气管哮喘的对接分析和预测疗效的可能性
7. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids:A randomized, placebo-controlled phase II trial (TREBLE) [O] . Simpson, Eric L., Flohr, Carsten, Eichenfield, Lawrence F., 2019

机译：Lebrikizumab（抗IL-13单克隆抗体）在局部至局部皮质类固醇激素控制不充分的中度至重度特应性皮炎成人中的疗效和安全性：一项随机，安慰剂对照的II期临床试验（TREBLE）
8. Short- and Long-Term Effects in Prostate Cancer Survival: Analysis of Treatment Efficacy and Risk Prediction [R] . Tsodikov, A. D. 2006

机译：前列腺癌生存的短期和长期影响：治疗效果分析和风险预测

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.

著录项

相似文献

相关主题

期刊订阅